XML 48 R33.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Licensing and Other Arrangements - Novartis - Additional Information (Details) $ / shares in Units, € in Millions |  |  | 3 Months Ended | 6 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | ---
Aug. 24, 2017 USD ($) Agreement Obligation $ / shares shares | Aug. 24, 2017 EUR (€) Agreement Obligation shares | Sep. 30, 2015 | Jun. 30, 2018 USD ($) | Jun. 30, 2017 USD ($) | Jun. 30, 2018 USD ($) | Dec. 31, 2017 USD ($) | Dec. 31, 2015 USD ($)
Novartis Pharma AG [Member] |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Upfront payment received | $ 25,700,000 |  |  |  |  |  |  |
Common stock aggregate fair value | 4,800,000 |  |  |  |  |  |  |
Common stock premium | $ 200,000 |  |  |  |  |  |  |
Number of license agreements | Agreement | 2 | 2 |  |  |  |  |  |
Number of performance obligations | Obligation | 2 | 2 |  |  |  |  |  |
Remaining performance obligations | $ 0 |  |  |  |  |  |  |
License agreement transaction price | 40,200,000 |  |  |  |  |  |  |
Contract liabilities |  |  |  | $ 0 |  | $ 0 | $ 0 |
Contract assets |  |  |  | 0 |  | 0 | 0 |
Revenue recognize |  |  |  | 0 |  | 0 |  |
Capitalized contract costs |  |  |  | 0 |  | 0 |  |
Novartis Pharma AG [Member] | Licenses and Related Materials, Process and Know-How and Filings to Regulatory Authority [Member] |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Recognized the entire transaction price as revenue upon completion of delivery |  |  |  |  |  |  | 40,200,000 |
Novartis Pharma AG [Member] | Common Stock [Member] |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Cash received from sale of shares | $ 5,000,000 |  |  |  |  |  |  |
Number of shares sold | shares | 539,131 | 539,131 |  |  |  |  |  |
Sale of stock price per share | $ / shares | $ 9.2742 |  |  |  |  |  |  |
Common stock closing price | $ / shares | $ 8.93 |  |  |  |  |  |  |
Novartis Pharma AG [Member] | Les Laboratories Servier [Member] |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Repayments of debt | $ 14,300,000 | € 12.0 |  |  |  |  |  |
Novartis Pharma AG [Member] | XOMA-052 License Agreement [Member] |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
License agreement consideration received | 30,000,000 |  |  |  |  |  |  |
Upfront payment received | 15,700,000 |  |  |  |  |  |  |
Eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones | $ 438,000,000 |  |  |  |  |  |  |
Agreement termination prior written notice period | 6 months | 6 months |  |  |  |  |  |
Novartis Pharma AG [Member] | IL-1 Target License Agreement [Member] |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Upfront payment received | $ 10,000,000 |  |  |  |  |  |  |
Novartis International [Member] |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Cash received from sale of shares | $ 5,000,000 |  |  |  |  |  |  |
Number of shares sold | shares | 539,131 | 539,131 |  |  |  |  |  |
Common stock aggregate fair value | $ 4,800,000 |  |  |  |  |  |  |
Common stock closing price | $ / shares | $ 8.93 |  |  |  |  |  |  |
Common stock premium | $ 200,000 |  |  |  |  |  |  |
Novartis International [Member] | License Agreement [Member] |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones |  |  |  |  |  | 470,000,000 |  |
Contract liabilities |  |  |  | 0 |  | 0 | 0 |
Contract assets |  |  |  | 0 |  | 0 | $ 0 |
Revenue recognize |  |  |  | 0 |  | 0 |  |
Capitalized contract costs |  |  |  | $ 0 |  | $ 0 |  |
Agreement termination notice period |  |  | 180 days |  |  |  |  |
Upfront payment recognized as revenue |  |  |  |  |  |  |  | $ 37,000,000
Milestone received under the collaboration agreement |  |  |  |  | $ 10,000,000 |  |  |

X
- Definition Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 340 -SubTopic 40 -Section 50 -Paragraph 3 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=68051541&loc=SL49131252-203054 + Details
Name: | us-gaap_CapitalizedContractCostNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130533-203044 + Details
Name: | us-gaap_ContractWithCustomerAssetNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized that was previously reported as deferred or unearned revenue. + References No definition available. + Details
Name: | us-gaap_DeferredRevenueRevenueRecognized1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585 + Details
Name: | us-gaap_RepaymentsOfDebt
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the value established as the selling price of the significant unit of accounting used to allocate the consideration of the multiple-deliverable arrangement. + References No definition available. + Details
Name: | us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Cash received on stock transaction after deduction of issuance costs. + References No definition available. + Details
Name: | us-gaap_SaleOfStockConsiderationReceivedOnTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Aggregate fair value of common stock. + References No definition available. + Details
Name: | xoma_AggregateFairValueOfCommonStock
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Agreement termination notice period. + References No definition available. + Details
Name: | xoma_AgreementTerminationNoticePeriod
Namespace Prefix: | xoma_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Agreement termination prior written notice period. + References No definition available. + Details
Name: | xoma_AgreementTerminationPriorWrittenNoticePeriod
Namespace Prefix: | xoma_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Closing stock price per share. + References No definition available. + Details
Name: | xoma_ClosingStockPricePerShare
Namespace Prefix: | xoma_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Common stock premium. + References No definition available. + Details
Name: | xoma_CommonStockPremium
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Eligible milestone payments receivable upon achievement of development regulatory and commercial milestones. + References No definition available. + Details
Name: | xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License agreement consideration received. + References No definition available. + Details
Name: | xoma_LicenseAgreementConsiderationReceived
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License agreement transaction price. + References No definition available. + Details
Name: | xoma_LicenseAgreementTransactionPrice
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Refers to the payment percentage of milestone received under the collaboration agreement. + References No definition available. + Details
Name: | xoma_MilestoneReceivedUnderCollaborationAgreement
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of license agreements. + References No definition available. + Details
Name: | xoma_NumberOfLicenseAgreements
Namespace Prefix: | xoma_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of performance obligations. + References No definition available. + Details
Name: | xoma_NumberOfPerformanceObligations
Namespace Prefix: | xoma_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Proceeds from upfront payment. + References No definition available. + Details
Name: | xoma_ProceedsFromUpfrontPayment
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront payment recognized as revenue. + References No definition available. + Details
Name: | xoma_UpfrontPaymentRecognizedAsRevenue
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=xoma_NovartisPharmaAGMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xoma_LicensesAndRelatedMaterialsProcessAndKnowHowAndFilingsToRegulatoryAuthorityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LineOfCreditFacilityAxis=xoma_LesLaboratoriesServierMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xoma_XOMA052LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xoma_IL1TargetLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xoma_NovartisInternationalPharmaceuticalLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |